Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


22 April, 2020

Scientific publications

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant


This study analyzed 220 SARS-CoV-2 genomic sequences from December 2019 to March 2020 to investigate viral mutations. Researchers identified eight novel recurrent mutation hotspots, finding different patterns in European and North American strains. A key mutation in the RNA-dependent-RNA polymerase (RdRp) gene, at position 14408, emerged in Italy in February 2020. Viruses with this RdRp mutation had a significantly higher number of point mutations (a median of 3 versus 1). This finding is critical as RdRp is a primary target for antiviral drugs, and this mutation's proximity to a predicted drug-binding site warrants investigation for potential drug resistance.

Pachetti et al., Journal of Translational Medicine | 2020